Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Pipeline Review, H2 2018’, provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

– The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

ImmunoGen Inc

Imugene Ltd

MediaPharma SRL

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Symphogen A/S

Taiho Pharmaceutical Co Ltd

Takis Srl

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Overview

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Companies Involved in Therapeutics Development

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

ImmunoGen Inc

Imugene Ltd

MediaPharma SRL

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Symphogen A/S

Taiho Pharmaceutical Co Ltd

Takis Srl

XuanZhu Pharma Co Ltd

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Drug Profiles

AV-203 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit EGFR and ERBB3 for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-3379 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elgemtumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-031 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2849330 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

huHER3-8 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-5209 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumretuzumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCLA-125 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPEV-201959 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit EGFR, ERBB2 and ERBB3 for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patritumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapitinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seribantumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-013 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-0728 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER1, HER2, HER3 and IGF1R for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER3 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5491 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Dormant Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) Product Development Milestones

Featured News & Press Releases

May 29, 2018: Merrimack to Present Data on Seribantumab at ASCO 2018 Annual Meeting

Apr 23, 2018: Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine

Apr 20, 2018: Celldex Therapeutics presents posters on CDX-3379 at the AACR Annual Meeting 2018

Apr 17, 2018: Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients

Mar 12, 2018: Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer

Feb 26, 2018: Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer

Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China

Nov 17, 2017: Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Oct 30, 2017: Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer

Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2

Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan

Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017

Sep 13, 2017: AVEO Oncology Announces Receipt of $0.5 million Payment from CANbridge

Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1)

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Pipeline by Celldex Therapeutics Inc, H2 2018

Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pipeline by Etubics Corp, H2 2018

Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Pipeline by Hummingbird Bioscience Pte Ltd, H2 2018

Pipeline by ImmunoGen Inc, H2 2018

Pipeline by Imugene Ltd, H2 2018

Pipeline by MediaPharma SRL, H2 2018

Pipeline by Merrimack Pharmaceuticals Inc, H2 2018

Pipeline by Merus NV, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Symphogen A/S, H2 2018

Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Pipeline by Takis Srl, H2 2018

Pipeline by XuanZhu Pharma Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports